Espresso-based method yields promising leads to ovarian most cancers trial

College of Kentucky Markey Most cancers Middle researchers introduced promising outcomes from an early-stage medical trial investigating a novel coffee-based method to ovarian most cancers upkeep remedy on the Society of Gynecologic Oncology annual assembly in Seattle (SGO 2025).

The research examined ArtemiCafe Decaf, a commercially accessible decaffeinated espresso product containing a managed dose of Artemisia annua, a plant that has been used medicinally for hundreds of years and is thought for its antimalarial properties. Current laboratory analysis has proven the plant may have anti-cancer properties.

Preliminary findings of the part 1 trial present that ArtemiCafe Decaf is secure and properly tolerated by sufferers at a dose of 4 cups each day. Extra affected person follow-up is required to find out its efficacy within the therapy of ovarian most cancers.

“This trial represents an essential step in exploring how Artemisia annua may assist sufferers with ovarian most cancers after they full commonplace therapies,” stated Frederick Ueland, M.D., a gynecologic oncologist with the UK Markey Most cancers Middle and research investigator. “Discovering a well-tolerated upkeep remedy that might probably delay or forestall recurrence could be transformative for ovarian most cancers care.”

The research, which was led by Jill Kolesar, Pharm.D., who now serves as dean of the College of Iowa School of Pharmacy, builds upon Markey Most cancers Middle’s ongoing analysis with Artemisia annua. Earlier laboratory research performed by Markey researchers demonstrated that artesunate, a compound derived from the Artemisia annua plant, confirmed robust anti-cancer exercise in opposition to ovarian most cancers cells at clinically achievable concentrations.

ArtemiCafe Decaf is at present being evaluated in a part 2 medical trial at Markey, which is concentrated on upkeep remedy for prostate most cancers sufferers.

“We’re proud to collaborate with the College of Kentucky’s Markey Most cancers Middle on this essential analysis,” stated ArtemiLife CEO Adam Maust. “Artemi’s mission is to help scientific advances whereas producing an progressive product to combine seamlessly into each day routines.”

Kentucky additionally has a particular connection to this analysis, as it’s at present the one state rising substantial quantities of Artemisia annua. The Kentucky Tobacco Analysis and Growth Middle on the UK Martin-Gatton School of Agriculture, Meals and Atmosphere at present grows the plant on the college’s Spindletop Farm; researchers throughout UK use the yields of that farm. ArtemiLife merchandise use Artemisia annua vegetation grown at two Kentucky farms in Georgetown and Lancaster.